ARGS Insider Trading Activity and SEC Form 4 Filings
ARGS insider trading summary
No open-market insider purchases or sales of Argos Therapeutics Inc (ARGS) have been reported on SEC Form 4 in the past 12 months.
Latest ARGS insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Jan 9, 2018 | Charles A. Nicolette | CSO and Vice President of R&D | Sell | $17K (100,250 @ $0.16) |
| Jan 9, 2018 | Lori R. Harrelson | Vice President of Finance | Sell | $11K (64,329 @ $0.16) |
| Jan 9, 2018 | Richard D Katz | Vice President and CFO | Sell | $17K (104,435 @ $0.16) |
| Jan 9, 2018 | Jeffrey D Abbey | President, CEO | Sell | $21K (124,987 @ $0.16) |
| Jan 3, 2018 | Charles A. Nicolette | CSO and Vice President of R&D | Sell | $15K (92,001 @ $0.16) |
| Jan 3, 2018 | Lori R. Harrelson | Vice President of Finance | Sell | $10K (59,072 @ $0.16) |
| Jan 3, 2018 | Richard D Katz | Vice President and CFO | Sell | $17K (101,228 @ $0.16) |
| Jan 3, 2018 | Jeffrey D Abbey | President, CEO | Sell | $19K (114,702 @ $0.16) |
| Jan 3, 2018 | Jeffrey D Abbey | President, CEO | Sell | $19K (114,702 @ $0.16) |
| Oct 7, 2016 | International S.A. Pharmstandard | 10% Owner | Buy | $99K (21,000 @ $4.73) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.